IMUGENE
Developing Cancer Immunotherapies

ASX Announcement

Imugene's PD1-Vaxx colorectal cancer trial to feature at ESMO 2025 Congress

Sydney, Australia, 20 October 2025: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, is pleased to announce that an abstract for the Neo-POLEM Phase II trial has been accepted for e-poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025, being held in Berlin, Germany, 17–21 October 2025.

The accepted abstract, titled "Phase II trial of neoadjuvant PD-1 vaccine PD1-Vaxx in operable MSI-high colorectal cancer", will be presented by Dr Tony Dhillon, Consultant Medical Oncologist at the Royal Surrey NHS Foundation Trust, United Kingdom.

The ESMO Congress is Europe's largest and most influential oncology meeting, attracting over 30,000 clinicians, researchers, patient advocates, and industry participants from around the world.

Imugene Managing Director and Chief Executive Officer Leslie Chong said: "We are delighted to see PD1-Vaxx recognised with presentation at the ESMO Congress, highlighting its growing international clinical footprint. The Neo-POLEM study marks an important expansion of our PD1-Vaxx program into early-stage colorectal cancer, an area where improved treatment options remain urgently needed."

Upon its release, the poster will be available on Imugene's website at https://imugene.com/investors/conference-presentations/

About the Neo-POLEM study

Neo-POLEM is a collaborative investigator-initiated Phase II clinical trial coordinated by the Southampton Clinical Trials Unit (UK) in partnership with the Australasian Gastro-Intestinal Trials Group (AGITG) and funded by Imugene Limited.

The trial is designed to determine whether PD1-Vaxx, Imugene's novel PD-1-targeting B-cell vaccine, can elicit major pathological responses in microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) early-stage colorectal cancer.

MSI-H colorectal tumours are characterised by high tumour mutation burden and immune infiltration, features that predict responsiveness to immunotherapy. PD1-Vaxx aims to induce a polyclonal B-cell antibody response against PD-1, potentially offering efficacy comparable to or greater than monoclonal antibody checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) while improving safety and accessibility.

The single-arm Bayesian optimal design trial will enrol 44 patients with operable MSI-high or dMMR stage II–III colon cancer across 6–10 sites in the UK and Australia. Participants receive three PD1-Vaxx vaccinations over six weeks prior to surgical resection, followed by investigator-selected adjuvant therapy. The primary endpoint is major pathological response (MPR), defined as ≤ 10% viable tumour cells at resection. Secondary endpoints include safety, complete response rate, objective response rate, disease-free and overall survival, and surgical outcomes.

Recruitment commenced in May 2025, with the study now open at multiple Australian sites and UK site activation underway.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited
Follow us on Twitter @TeamImugene
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours and B-cell vaccine candidates. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.